No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Nanosonics Limited, along with its subsidiaries, functions as a global infection prevention enterprise with operations in Australia and beyond. The company focuses on the production and distribution of its trophon ultrasound probe disinfection system, including all related supplies and accessories. Additionally, it dedicates resources to the exploration, development, and market launch of innovative infection control, decontamination products, and their associated technologies. Key offerings from Nanosonics include trophon2, an advanced device for high-level disinfection of ultrasound probes; trophon EPR, a low-temperature, high-level disinfection method specifically for intra-cavity ultrasound probes; and Nanosonics AuditPro, a comprehensive solution for managing compliance with infection control workflows. Established in 2000, Nanosonics Limited is headquartered in Macquarie Park, Australia.
www.nanosonics.com.auNo one on the platform currently holds NAN.AX.
No tracked institution reports a position in NAN.AX as of their last filing.
No one on the platform has traded NAN.AX yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 15.6% | 15.0% | 25.4% | — | — | — |
| Rev. Growth % | 2.3% | 14.8% | ||||
| Profit Margin % | 8.8% | 8.3% | 12.5% | |||
| Free Cash Flow Margin % | 8.6% | 9.9% | 11.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $220M | +3.7% | $0.03 | $0.02–$0.04 | — | 5 |
| 2028 | $239M | +9.0% | $0.04 | $0.01–$0.08 | — | 6 |
| 2029 | $260M | +8.7% | $0.06 | $0.03–$0.10 | — | 6 |
| 2030 | $327M | +25.6% | $0.14 | $0.13–$0.14 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 7 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-24 | $0.02 | $0.03 | +15.7% |
| 2026-02-24 | $0.03 | $0.03 | -0.4% |
| 2025-08-25 | $0.03 | $0.04 | +17.6% |
| 2025-02-19 | $0.02 | $0.03 | +46.7% |
| 2024-08-27 | $0.02 | $0.02 | +25.8% |
| 2024-02-27 | $0.01 | $0.02 | +51.4% |
| 2023-08-23 | $0.02 | $0.03 | +54.7% |
| 2023-02-23 | $0.03 |
| $0.03 |
| +12.3% |
| $330M |
| — |
| IDX.AXIntegral Diagnostics Limited | $2.31 | +0.43% | $862M | — |
| PGC.AXParagon Care Limited | $0.13 | +0.00% | $215M | — |
Source: Financial Modeling Prep · peers by sector/industry